Cerebral Adrenoleukodystrophy (CALD) Market Report 2026

The cerebral adrenoleukodystrophy (cald) market size has grown rapidly in recent years. It will grow from $7.54 billion in 2025 to $8.64 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to improved genetic understanding of ald, availability of stem cell transplantation options, expansion of rare disease registries, increased awareness among neurologists, growth of specialty treatment centers.

The cerebral adrenoleukodystrophy (cald) market size is expected to see rapid growth in the next few years. It will grow to $14.72 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing adoption of gene therapy solutions, rising investments in rare disease drug development, expansion of newborn screening initiatives, growing focus on personalized treatment approaches, increasing collaboration between research and clinical centers. Major trends in the forecast period include increasing research into gene therapy approaches, growing use of early diagnostic screening programs, expansion of stem cell transplantation treatments, rising focus on rare disease awareness, enhanced supportive care management.

The gradual increase in healthcare spending is anticipated to drive the growth of the cerebral adrenoleukodystrophy (CALD) market in the coming years. Healthcare expenditure is rising due to factors such as aging populations, a growing burden of chronic diseases, medical and technological advancements, increasing drug prices, and the expansion of health insurance coverage. Higher healthcare spending supports cerebral adrenoleukodystrophy (CALD) by facilitating progress in diagnostic technologies, financing innovative therapies such as gene therapy and stem cell transplantation, and improving patient access to specialized care and early intervention services. For instance, in December 2024, according to the Centers for Medicare and Medicaid Services (CMS), a US-based federal agency, national health expenditures (NHE) increased by 7.5% in 2023, surpassing gross domestic product (GDP) growth of 6.1%. From 2023 to 2032, national health expenditures are projected to grow at an average annual rate of 5.6%, raising healthcare spending as a share of GDP from 17.3% in 2022 to 19.7% by 2032. Therefore, rising healthcare expenditure is fueling the growth of the cerebral adrenoleukodystrophy (CALD) market.

Major companies operating in the cerebral adrenoleukodystrophy (cALD) market are increasingly emphasizing the development of innovative oral small-molecule therapies, such as selective PPARγ agonists, to strengthen neuroprotective effects, enhance central nervous system penetration, and provide safer and more convenient alternatives to invasive or less targeted treatment options. A PPARγ agonist (peroxisome proliferator-activated receptor gamma agonist) is a class of compounds that activate the PPARγ receptor, a nuclear hormone receptor primarily expressed in adipose tissue, immune cells, and muscle tissue. For instance, in May 2023, Minoryx Therapeutics, a Spain-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) to initiate its Phase 3 CALYX clinical trial of leriglitazone (MIN-102). Leriglitazone is a novel, orally administered, brain-penetrant, and selective PPARγ agonist designed to address key disease mechanisms in cALD, including neuroinflammation, mitochondrial dysfunction, demyelination, and axonal degeneration. Unlike conventional treatment approaches such as hematopoietic stem cell transplantation (HSCT) or gene therapy, which are invasive, carry significant risks, and may not be suitable for many adult patients, leriglitazone represents a non-cellular, potentially safer, and more accessible therapeutic option. In compassionate-use studies, leriglitazone has demonstrated good tolerability and the ability to stabilize both clinical and radiological disease indicators in adult cALD patients.

In June 2025, Carlyle, a US-based global investment firm, and SK Capital Partners, a US-based private equity company focused on specialty materials and life sciences, jointly completed the acquisition of bluebird bio for an undisclosed amount. This acquisition is intended to accelerate the development and commercialization of advanced cell and gene therapies by providing increased capital resources, strategic guidance, and operational scale. bluebird bio is a US-based biotechnology company engaged in developing therapies for cerebral adrenoleukodystrophy.

Major companies operating in the cerebral adrenoleukodystrophy (cald) market are Bluebird Bio Inc., Minoryx Therapeutics S.L., SwanBio Therapeutics Inc., Magenta Therapeutics Inc., Novartis AG, Vertex Pharmaceuticals Inc., MedDay Pharmaceuticals SAS, SOM Biotech Inc., Autobahn Therapeutics Inc., Orpheris Inc., Sperogenix Therapeutics Inc., NeuroVia Inc., REGENXBIO Inc., Ultragenyx Pharmaceutical Inc., Taysha Gene Therapies Inc., Neurogene Inc., Applied Genetic Technologies Corporation, Oxford BioMedica plc, UniQure N.V.

North America was the largest region in the cerebral adrenoleukodystrophy (CALD) market in 2025. The regions covered in the cerebral adrenoleukodystrophy (cald) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cerebral adrenoleukodystrophy (cald) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cerebral adrenoleukodystrophy market by increasing costs of imported gene therapy vectors, stem cell processing equipment, diagnostic reagents, and specialized pharmaceutical inputs. Healthcare facilities and research institutions in North America and Europe are most affected due to dependence on globally sourced rare disease therapies, while Asia-Pacific faces cost pressures on advanced treatment imports. These tariffs are increasing therapy costs and affecting access timelines. However, they are also encouraging domestic research capabilities, regional manufacturing of advanced therapeutics, and increased public-private investment in rare disease treatment infrastructure.

The cerebral adrenoleukodystrophy (cald) market research report is one of a series of new reports that provides cerebral adrenoleukodystrophy (cald) market statistics, including cerebral adrenoleukodystrophy (cald) industry global market size, regional shares, competitors with a cerebral adrenoleukodystrophy (cald) market share, detailed cerebral adrenoleukodystrophy (cald) market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral adrenoleukodystrophy (cald) industry. This cerebral adrenoleukodystrophy (cald) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cerebral adrenoleukodystrophy (CALD) is a rare and progressive neurological disorder that predominantly affects males and results from mutations in the ABCD1 gene. It is marked by the buildup of very long-chain fatty acids in the brain, leading to the destruction of myelin, the protective sheath surrounding nerve cells. CALD is a subtype of adrenoleukodystrophy (ALD) that involves the brain and spinal cord and causes symptoms such as cognitive impairment, behavioral changes, and motor dysfunction.

The main treatment approaches for cerebral adrenoleukodystrophy (CALD) include dietary management, medications, and stem cell therapy. Dietary management involves adjusting the patient’s diet to help control CALD-related symptoms. The condition affects various patient age groups, including adults, children, infants, and teenagers, and treatment options are utilized by end users such as healthcare facilities, patients and caregivers, and pharmaceutical companies.

The cerebral adrenoleukodystrophy (CALD) market consists of revenues earned by entities by providing services such as genetic testing, diagnostic imaging, medical consultations, hematopoietic stem cell transplantation, patient monitoring, counseling and long-term care management for individuals affected by cerebral adrenoleukodystrophy (CALD). The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral adrenoleukodystrophy (CALD) market also includes sales of gene therapies, corticosteroids and supportive care treatments aimed at managing symptoms and slowing disease progression. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.